Parkinson's disease and RLS: the dopaminergic bridge

被引:74
作者
Rye, DB [1 ]
机构
[1] Emory Univ, Sch Med, Program Sleep Med, Atlanta, GA 30322 USA
关键词
restless legs syndrome; dopamine; Parkinson's disease;
D O I
10.1016/j.sleep.2004.01.016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Dopamine is a neurotransmitter that modulates diverse waking behaviors including movement, motivation, cognition, reward, and feeding Interest in dopamine's additional contributions to normal and pathologic sleep-wake states has experienced a recent rebirth originating from two clinical disorders: Parkinson's disease and Restless Legs Syndrome. The former, the prototypical disorder of brain dopamine cell loss, is accompanied by marked sleep disruption and impairments in daytime alertness. The latter is exquisitively responsive to pharmacologic agents that act upon dopamine receptors. The potential neurobiological substrates underlying these observations are reviewed here. Converging lines of evidence suggest that mesocorticolimbic dopamine circuits are involved in promoting wakefulness, while a less studied diencephalospinal dopamine system might underly the sensorimotor dysfunction of Restless Legs Syndrome. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:317 / 328
页数:12
相关论文
共 173 条
[71]   EVIDENCE FOR A DOPAMINERGIC PATHWAY IN THE RAT DESCENDING FROM THE A11-CELL GROUP TO THE SPINAL-CORD [J].
HOKFELT, T ;
PHILLIPSON, O ;
GOLDSTEIN, M .
ACTA PHYSIOLOGICA SCANDINAVICA, 1979, 107 (04) :393-395
[72]  
Holstege JC, 1996, J COMP NEUROL, V376, P631, DOI 10.1002/(SICI)1096-9861(19961223)376:4<631::AID-CNE10>3.0.CO
[73]  
2-P
[74]   Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep (vol 10, pg 3111, 1999) [J].
Honda, K ;
Riehl, J ;
Mignot, E ;
Nishino, S .
NEUROREPORT, 1999, 10 (17) :3717-3724
[75]   DIURNAL ALTERATIONS OF CATECHOLAMINES, INDOLEAMINES AND THEIR METABOLITES IN SPECIFIC BRAIN-REGIONS OF THE MOUSE [J].
HUIE, JM ;
SHARMA, RP ;
COULOMBE, RA .
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-PHARMACOLOGY TOXICOLOGY & ENDOCRINOLOGY, 1989, 94 (02) :575-579
[76]  
Ilinsky IA, 1999, J COMP NEUROL, V409, P369
[77]   The dopamine transporter: A crucial component regulating dopamine transmission [J].
Jaber, M ;
Jones, S ;
Giros, B ;
Caron, MG .
MOVEMENT DISORDERS, 1997, 12 (05) :629-633
[78]   THE PEDUNCULOPONTINE NUCLEUS IN PARKINSONS-DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY AND ALZHEIMERS-DISEASE [J].
JELLINGER, K .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1988, 51 (04) :540-543
[79]   PATHOLOGY OF PARKINSONS-DISEASE - CHANGES OTHER THAN THE NIGROSTRIATAL PATHWAY [J].
JELLINGER, KA .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1991, 14 (03) :153-197
[80]   EFFECT OF LESIONS OF CATECHOLAMINE-CONTAINING NEURONS UPON MONOAMINE CONTENT OF BRAIN AND EEG AND BEHAVIORAL WAKING IN CAT [J].
JONES, BE ;
BOBILLIE.P ;
PIN, C ;
JOUVET, M .
BRAIN RESEARCH, 1973, 58 (01) :157-177